FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362400047> ?p ?o ?g. }

• W4362400047 abstract "<p>Supplementary Figure 1. Schematic of LINCS library chemical screen. Supplementary Figure 2. Selectivity of LINCS library kinase inhibitors toward mutant NRAS-expressing cells. Supplementary Figure 3. Proliferation studies showing positive combination effects between AZD6244 and LINCS library inhibitors. Supplementary Figure 4. Treatment of Ba/F3-NRAS-G12D cells with GSK1904529A, AZD6244, or a combination of both in the presence of RPMI+10% FBS or RPMI+10�S supplemented with 15% WEHI-conditioned medium (used as a source of IL-3). Supplementary Figure 5. Investigation of the combined effects of IGF-1R inhibition and MEK inhibition on RAS and IGF-1R protein expression in RAS-transformed cells. Supplementary Figure 6 (A-E). Induction of apoptosis in AZD6244 and GSK1904529A-treated wt and mutant RAS-expressing AML cell lines. Supplementary Figure 6 (F-I). Cell cycle progression of AZD6244 and GSK1904529A-treated mutant RAS-expressing cells. Supplementary Figure 6 (J-L). Effects of the combination of IGF-1R inhibitor, GSK1904529A (75 nM), and the Mek inhibitor, AZD6244 (20 nM), on cell cycle progression and induction of apoptosis of Ba/F3-NRAS-G12D cells. Supplementary Figure 6 (M). Effects of the combination of GSK1904529A (37.5 nM) and AZD6244 (37.5 nM) on cell cycle progression of Ba/F3-KRAS-G12D cells. Supplementary Figure 6 (N). Effects of the combination of GSK1904529A (300 nM) and AZD6244 (300 nM) on soft agar colony growth of wt RAS-expressing MOLM14 cells, mutant KRAS-expressing NB4 cells, and mutant NRAS-expressing OCI-AML3 cells. Supplementary Figure 7 (part 1). Treatment of human AML cells with GSK1904529A, AZD6244, or a combination of both in the presence of RPMI+10% FBS, 95% HS-5 SCM, or 95% HS27a SCM. Supplementary Figure 7 (part 2). Treatment of human AML cells with GSK1904529A, AZD6244, or a combination of both in the presence of RPMI+10% FBS, 95% HS-5 SCM, or 95% HS27a SCM. Supplementary Figure 8. Heightened response of mutant RAS-expressing HL60 cells to IGF as compared to Hel cells. Supplementary Figure 9. Investigation of the combined effects of GSK1904529A and the PI3K inhibitor, ZSTK474, against wild-type or mutant RAS-expressing Ba/F3 cells. Supplementary Figure 10. Investigation of phospho- and total-Erk1/Erk2 and phospho and total IGF-1R levels in wt and mutant RAS-expressing human AML cell lines. Supplementary Figure 11. MEK inhibition as a predictor of response to IGF-1R and MEK inhibitor combination treatment. Supplementary Figure 12. Effects of NVPAEW541 on IGF-1R (A) and Erk1/Erk2 (B) phosphorylation. Supplementary Figure 13. Investigation of the combined effects of IGF-1R inhibition and MEK inhibition on phosphorylation of Erk1/Erk2 (A) and AKT (B) in mutant RAS-expressing cells. Supplementary Figure 14. Investigation of the combined effects of IGF-1R inhibition and MEK inhibition on phospho-4E-BP1 (Serine 65) expression in mutant RAS-expressing cells. Supplementary Figure 15. Effects of IGF-1R KD in the mutant KRAS-expressing human cell line, NB4, and wt RAS-expressing human cell line, Hel. Supplementary Figure 16. Mouse spleen measurements from in vivo leukemia study investigating the effects of NVPAEW541, AZD6244, or NVPAEW541+AZD6244 treatment of mice tail vein-injected with OCI-AML3-luc+ cells. Supplementary Figure 17. Combined effects of IGF-1R and MEK inhibition against mutant NRAS-positive AML patient cells.</p>" @default.
• W4362400047 created "2023-04-05" @default.
• W4362400047 creator A5012712111 @default.
• W4362400047 creator A5019034689 @default.
• W4362400047 creator A5021555728 @default.
• W4362400047 creator A5022352605 @default.
• W4362400047 creator A5034151974 @default.
• W4362400047 creator A5039503690 @default.
• W4362400047 creator A5047404508 @default.
• W4362400047 creator A5055853326 @default.
• W4362400047 creator A5056391726 @default.
• W4362400047 creator A5062083804 @default.
• W4362400047 creator A5063514278 @default.
• W4362400047 creator A5067580558 @default.
• W4362400047 creator A5069230015 @default.
• W4362400047 creator A5076875138 @default.
• W4362400047 date "2023-03-31" @default.
• W4362400047 modified "2023-09-29" @default.
• W4362400047 title "Supplementary Figures from Upregulation of IGF1R by Mutant <i>RAS</i> in Leukemia and Potentiation of <i>RAS</i> Signaling Inhibitors by Small-Molecule Inhibition of IGF1R" @default.
• W4362400047 doi "https://doi.org/10.1158/1078-0432.22460778" @default.
• W4362400047 hasPublicationYear "2023" @default.
• W4362400047 type Work @default.
• W4362400047 citedByCount "0" @default.
• W4362400047 crossrefType "posted-content" @default.
• W4362400047 hasAuthorship W4362400047A5012712111 @default.
• W4362400047 hasAuthorship W4362400047A5019034689 @default.
• W4362400047 hasAuthorship W4362400047A5021555728 @default.
• W4362400047 hasAuthorship W4362400047A5022352605 @default.
• W4362400047 hasAuthorship W4362400047A5034151974 @default.
• W4362400047 hasAuthorship W4362400047A5039503690 @default.
• W4362400047 hasAuthorship W4362400047A5047404508 @default.
• W4362400047 hasAuthorship W4362400047A5055853326 @default.
• W4362400047 hasAuthorship W4362400047A5056391726 @default.
• W4362400047 hasAuthorship W4362400047A5062083804 @default.
• W4362400047 hasAuthorship W4362400047A5063514278 @default.
• W4362400047 hasAuthorship W4362400047A5067580558 @default.
• W4362400047 hasAuthorship W4362400047A5069230015 @default.
• W4362400047 hasAuthorship W4362400047A5076875138 @default.
• W4362400047 hasBestOaLocation W43624000471 @default.
• W4362400047 hasConcept C104317684 @default.
• W4362400047 hasConcept C143065580 @default.
• W4362400047 hasConcept C153911025 @default.
• W4362400047 hasConcept C184235292 @default.
• W4362400047 hasConcept C190283241 @default.
• W4362400047 hasConcept C21790070 @default.
• W4362400047 hasConcept C2779084600 @default.
• W4362400047 hasConcept C2779707156 @default.
• W4362400047 hasConcept C2781187634 @default.
• W4362400047 hasConcept C2781249067 @default.
• W4362400047 hasConcept C29537977 @default.
• W4362400047 hasConcept C501734568 @default.
• W4362400047 hasConcept C502942594 @default.
• W4362400047 hasConcept C54355233 @default.
• W4362400047 hasConcept C55493867 @default.
• W4362400047 hasConcept C57074206 @default.
• W4362400047 hasConcept C81885089 @default.
• W4362400047 hasConcept C86803240 @default.
• W4362400047 hasConcept C95444343 @default.
• W4362400047 hasConcept C97029542 @default.
• W4362400047 hasConceptScore W4362400047C104317684 @default.
• W4362400047 hasConceptScore W4362400047C143065580 @default.
• W4362400047 hasConceptScore W4362400047C153911025 @default.
• W4362400047 hasConceptScore W4362400047C184235292 @default.
• W4362400047 hasConceptScore W4362400047C190283241 @default.
• W4362400047 hasConceptScore W4362400047C21790070 @default.
• W4362400047 hasConceptScore W4362400047C2779084600 @default.
• W4362400047 hasConceptScore W4362400047C2779707156 @default.
• W4362400047 hasConceptScore W4362400047C2781187634 @default.
• W4362400047 hasConceptScore W4362400047C2781249067 @default.
• W4362400047 hasConceptScore W4362400047C29537977 @default.
• W4362400047 hasConceptScore W4362400047C501734568 @default.
• W4362400047 hasConceptScore W4362400047C502942594 @default.
• W4362400047 hasConceptScore W4362400047C54355233 @default.
• W4362400047 hasConceptScore W4362400047C55493867 @default.
• W4362400047 hasConceptScore W4362400047C57074206 @default.
• W4362400047 hasConceptScore W4362400047C81885089 @default.
• W4362400047 hasConceptScore W4362400047C86803240 @default.
• W4362400047 hasConceptScore W4362400047C95444343 @default.
• W4362400047 hasConceptScore W4362400047C97029542 @default.
• W4362400047 hasLocation W43624000471 @default.
• W4362400047 hasOpenAccess W4362400047 @default.
• W4362400047 hasPrimaryLocation W43624000471 @default.
• W4362400047 hasRelatedWork W1973794173 @default.
• W4362400047 hasRelatedWork W2339535453 @default.
• W4362400047 hasRelatedWork W2897682253 @default.
• W4362400047 hasRelatedWork W2995994395 @default.
• W4362400047 hasRelatedWork W3212888956 @default.
• W4362400047 hasRelatedWork W4200179277 @default.
• W4362400047 hasRelatedWork W4308447204 @default.
• W4362400047 hasRelatedWork W4361919600 @default.
• W4362400047 hasRelatedWork W4362400047 @default.
• W4362400047 hasRelatedWork W4367603577 @default.
• W4362400047 isParatext "false" @default.
• W4362400047 isRetracted "false" @default.
• W4362400047 workType "article" @default.